Antibody-drug conjugates (ADCs) are a rapidly expanding class of biotherapeutics that
utilize antibodies to selectively deliver cytotoxic drugs to the tumor site. As of May 2021, the …

Antibody-drug conjugates (ADCs) are a promising class of immunotherapies with the
potential to specifically target tumor cells and ameliorate the therapeutic index of cytotoxic …

Drug conjugates, including antibody-drug conjugates, are a step toward realizing Paul
Ehrlich's idea from over 100 years ago of a “magic bullet” for cancer treatment. Through …

Bromodomain and extra-terminal domain (BET) proteins, cyclic adenosine monophosphate
response element-binding protein (CBP), and the E1A-binding protein of p300 (EP300) are …

Anti-tubulin agents constitute a large class of compounds with broad activity both in solid
tumors and hematologic malignancies, due to the interference with microtubule dynamics …

Antibody-drug conjugates (ADCs) are a recent, revolutionary approach for malignancies
treatment, designed to provide superior efficacy and specific targeting of tumor cells …

Inhibitors of phosphatidylinositol 3-kinase (PI3K) and Bruton tyrosine kinase (BTK) represent
a recognized option for the treatment of patients affected by indolent B cell lymphomas …

Antibody-drug conjugates offer the possibility of directing powerful cytotoxic agents to a
malignant tumor while sparing normal tissue. The challenge is to select an antibody target …

PI3Kδ inhibitors are active in patients with lymphoid neoplasms and a first series of them
have been approved for the treatment of multiple types of B-cell lymphoid tumors, including …

PI3K delta (PI3Kδ) inhibitors are used to treat lymphomas but safety concerns and limited
target selectivity curbed their clinical usefulness. PI3Kδ inhibition in solid tumors has …